Recent Patents on Endocrine, Metabolic and Immune Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Better targeting melanoma: options beyond surgery and conventional chemotherapy.
Authors: Kyrgidis A, Valasidis A, Bourlidou E, Andreadis C Abstract Skin cancer is the commonest malignant tumour in white skinned individuals in the western world. The incidence of skin cancer is on the rise. Case fatality for melanoma is probably the highest, not only among skin cancers but also among all types of cancers. The notion that cancer stem cells are responsible for disease progress and development has lead researchers towards these initiators of new metastases. Intra- and extracellular path inhibitors are targeted in eliminating crucial functions of tumor cells. Treatments are easily escaped f...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Adrenomedullin: exciting new horizons.
Authors: Cheung BM, Tang F Abstract Adrenomedullin is a peptide initially isolated from pheochromocytoma. It has a wide distribution and has multiple actions in many systems including the cardiovascular, renal, endocrine, reproductive, immune, nervous and musculoskeletal systems. This is reflected in the patents. These cover the use of adrenomedullin in diagnosis and as a biomarker for prognosis, especially in cardiovascular diseases and diabetes. It has also been proposed as a therapeutic agent, as a method to promote regeneration and repair, such as in ischaemic conditions and bone fractures. Conversely,...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Emerging therapies for dyslipidemia: known knowns and known unknowns of MTP inhibitors.
Authors: Raval SK, Raval PS, Jain MR Abstract Last decade had witnessed enormous efforts to develop therapies to treat one or more components of metabolic syndrome, a cluster of diseases including diabetes, obesity and dyslipidemia. Several newer targets are identified and evaluated to treat these metabolic disorders. Microsomal triglyceride transfer protein (MTP) has been identified as one of the promising target for the treatment of dyslipidemia. MTP plays crucial role in the assembly of triglyceride rich chylomicrones in enterocytes and VLDL in hepatocytes and several lines of evidence suggested that MT...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Editorial.
Authors: Zaman K PMID: 22264212 [PubMed - as supplied by publisher] (Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery)
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Melatonin in bacterial and viral infections with focus on sepsis: a review.
Authors: Srinivasan V, Mohamed M, Kato H Abstract Melatonin is a versatile molecule, synthesized not only by the pineal gland, but also in small amounts by many other organs like retina, gastrointestinal tract, thymus, bone marrow, lymphocytes etc. It plays an important role in various functions of the body like sleep and circadian rhythm regulation, immunoregulatory mechanism, free radical scavenger, antioxidant functions, oncostatic actions, control of reproductive functions, regulation of mood etc. Melatonin has also been found to be effective in combating various bacterial and viral infections. Its adm...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Present and future of adeno associated virus based gene therapy approaches.
Authors: Ortolano S, Spuch C, Navarro C Abstract During the last 20 years, transgenic constructs based on adeno associated virus (AAV) have been tested in disease models and proved their efficacy to revert a wide range of pathologies without major side effects. Based on these results, up to 20 clinical trials have been set up to prove therapeutic effect of AAV vectors on neurodegenerative diseases, retinopathies and neuromuscular diseases, among others. It has been shown that AAV vectors support localized long-term, gene expression in the central nervous system, and that restoration of visual function can ...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Degludec: A Novel Basal Insulin.
Authors: Kalra S, Baruah MP, Niazi AK Abstract Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these limitations. This paper reviews the potential advantages of degludec over existing basal insulins and analogs. It discusses the basic and clinical studies performed on degludec so far, and highlights the possibl...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

An important addition to the 'Recent Patent' journal series.
Authors: Zaman K PMID: 22280220 [PubMed - indexed for MEDLINE] (Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery)
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Degludec: a novel basal insulin.
Authors: Kalra S, Baruah MP, Niazi AK Abstract Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulins. Degludec, a novel basal insulin analog has the potential to overcome these limitations. This paper reviews the potential advantages of degludec over existing basal insulins and analogs. It discusses the basic and clinical studies performed on degludec so far, and highlights the possib...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Pleiotropic effects of omega-3 fatty acids.
Authors: Papazafiropoulou AK, Kardara MS, Pappas SI Abstract Omega-3 fatty acids except for their effect on triglycerides levels have cardioprotective properties as well as antiarrhythmic properties.The pleiotropic effects of omega-3 fatty acids, also, include lowering of blood pressure and the favorable effect on endothelial function and high-density cholesterol levels. Furthermore, studies have showed their favorable action in subjects with dementia, Alzheimer's disease and learning disorders. In this paper, a review of the recent patents on omega-3 fatty acids will be presented. PMID: 22280222 [...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Anti diabetic effect of cherries in alloxan induced diabetic rats.
In this study 36 Male Wistar rats, body weight of 150-200gr were divided into 6 groups. Diabetes was induced by intra peritoneal injection of 120 mg/kg Alloxan. The duration of the cherries treatment was 30 days in which single dose of extracts (200mg/kg) were oral administered to diabetic rats. Blood glucose levels were estimated with glucometer before treatment, 2h and 1- 4 weeks after administration of extracts. Treatment with extracts of the cherries resulted in a significant reduction in blood glucose and urinary microalbumin and an increase in the creatinine secretion level in urea. Extract of this plant is useful in...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Osteoblastic responses to LPS, glucose-oxidised LDL and minocycline: therapeutic targets for periodontal and cardiometabolic diseases.
CONCLUSIONS: Decreased yields of the oxidative stress marker DHT in response to LPS, G and GLDL were overcome in the presence of minocycline, which demonstrates its potential role as an adjunctive therapeutic agent in an environment of oxidative stress. These applications could be extrapolated to periodontal disease and co-existing cardiometabolic risk markers, in the context of its antiinflammatory and antioxidant actions relevant to healing. In this paper, recent patents relevant to adjunctive therapeutic management of periodontal disease co-existing with cardiometabolic risk markers are addressed. There have been signif...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Breast cancer therapy based on melatonin.
Authors: Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Rueda N Abstract The usefulness of melatonin and melatoninergic drugs in breast cancer therapy is based on its Selective Estrogen Receptor Modulator (SERM) and Selective Estrogen Enzyme Modulator (SEEM) properties. Because of the oncostatic properties of melatonin, its nocturnal suppression by light-at-night (LAN) has been considered a risk-factor for breast cancer. Melatonin's SERM actions include modulation of estrogen-regulated cell proliferation, invasiveness and expression of proteins, growth factors and proto-oncogenes (hTERT, p53, p21, T...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
Authors: Spuch C, Ortolano S, Navarro C Abstract Lafora disease (LD) is a fatal autosomal recessive form of progressive myoclonus epilepsy. Patients manifest myoclonus and tonic-clonic seizures, visual hallucinations, intellectual, and progressive neurologic deterioration beginning in adolescence. The two genes known to be involved in Lafora disease are EPM2A and NHLRC1 (EPM2B). The EPM2A gene encodes laforin, a dual-specificity protein phosphatase, and the NHLRC1 gene encodes malin, an E3-ubiquitin ligase. The two proteins interact with each other and, as a complex, are thought to regulate glycogen synthe...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research

Subclinical hypothyroidism and homeostatic disturbances: case report and literature review.
Authors: Ehsanzadeh-Cheemeh P, Thompson M, Miller M Abstract Abnormalities of coagulation have been reported in patients with thyroid dysfunction, although there is no clear information to explain the mechanism behind such irregularities. We are presenting a case of subclinical hypothyroidism that came with coagulation disturbance (hypocoagulation). Her symptoms resolved with leothyroxin in 4 weeks. Further studies are needed to clear the pathogenesis of the coagulation disturbance in such setting. The article also outlines some patents on hypothyroidism and hyperthyroidism. PMID: 22435391 [PubMed ...
Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research